Prof Andrea Filippi talks to ecancer about his ongoing phase II study of durvalumab following radiotherapy in patients with unresectable, stage 3 non-small-cell lung cancer ineligible for chemotherapy, currently still enrolling.
Prof Filippi begins by giving a brief overview of the trial outlining the background of the study and touching on the eligibility of patients for the study and the length of time different patients will receive durvalumab.
He then goes on to talk in more detail about the methodology used for the study, covering factors in choosing patients, study conditions, drug doses and measuring progression-free survival.
To conclude, Prof Filippi talks about the next steps for the study expressing that it can serve as a platform for building up new protocols for research in elderly patients who aren't typically considered for clinical trials.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.